Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 26
Filtrer
1.
ANZ J Surg ; 2024 Sep 10.
Article de Anglais | MEDLINE | ID: mdl-39253994

RÉSUMÉ

PURPOSE: Radiation-induced angiosarcoma (RIAS) of the breast is a rare tumour with high rate of local recurrence. The aim of this study is to evaluate the outcome of radical resections. METHODS: A retrospective analysis of all patients who underwent extended surgical resection for RIAS of the breast between 2013 and 2022. Included were patients who underwent radical resection, including complete resection of previously irradiated skin and underlying fascia of pectoralis major. Post-operative and long-term oncological outcomes were than analysed. A systematic review was performed using the MEDLINE database in the last 20 years. RESULTS: Twenty-two (n = 22) patients met the inclusion criteria. The median length of the specimen was 220 mm (range, 120-377 mm). At a median follow-up of 33.5 months (range, 7.9-102.4), 3 (13.6%) patients had both local and metastatic lung disease and 1 (4%) patient with only lung metastasis. The estimated 3- and 5-year OS was 81.1% and 57.9%, respectively. The estimated 3- and 5-year DSS was 91.7% and 65.5%, respectively. The estimated 3- and 5-year DFS rate were both 75.2%. The systematic review identified 17 studies with a recurrence rate ranging from 33% to 100%. CONCLUSIONS: Treatment of RIAS of the breast with an up-front locally extended approach is associated with a low rate of local recurrence compared with the reported literature.

4.
Ann Surg Oncol ; 2024 Jun 19.
Article de Anglais | MEDLINE | ID: mdl-38898325

RÉSUMÉ

BACKGROUND: Retroperitoneal sarcomas (RPSs) present a surgical challenge, with complex anatomic relationships to organs and vascular structures. This pilot study investigated the role of three-dimensional (3D) augmented reality (3DAR) compared with standard imaging in preoperative planning and resection strategies. METHODS: For the study, 13 patients who underwent surgical resection of their RPS were selected based on the location of their tumor (right, left, pelvis). From the patients' preoperative computed tomography (CT) scans, 3DAR models were created using a D2P program and projected by an augmented-reality (AR) glass (Hololens). The 3DAR models were evaluated by three experienced sarcoma surgeons and compared with the baseline two-dimensional (2D) contrast-enhanced CT scans. RESULTS: Three members of the surgical team evaluated 13 models of retroperitoneal sarcomas, resulting in a total of 26 responses. When the surgical team was asked to evaluate whether the 3DAR better prepared the surgeon for planned surgical resection, 10 responses favored the 3DAR, 5 favored the 2D CT scans and 11 showed no difference (p = 0.074). According to 15 (57.6 %) of the 26 responses, the 3DAR offered additional value over standard imaging in the preoperative planning (median score of 4; range, 1-5). The median stated likelihood that the surgeons would consult the 3DAR was 5 (range, 2-5) for the preoperative setting and 3 (range, 1-5) for the intraoperative setting. CONCLUSIONS: This pilot study suggests that the use of 3DAR may provide additional value over current standard imaging in the preoperative planning for surgical resection of RPS, and the technology merits further study.

5.
Eur J Surg Oncol ; 50(6): 108050, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38498966

RÉSUMÉ

BACKGROUND: Isolated limb perfusion (ILP) is a well-established surgical procedure for the administration of high dose chemotherapy to a limb for the treatment of advanced extremity malignancy. Although the technique of ILP was first described over 60 years ago, ILP is utilised in relatively few specialist centres, co-located with tertiary or quaternary cancer centres. The combination of high dose cytotoxic chemotherapy and the cytokine tumour necrosis factor alpha (TNFα), mandates leakage monitoring to prevent potentially serious systemic toxicity. Since the procedure is performed at relatively few specialist centres, an ILP working group was formed with the aim of producing technical consensus guidelines for the procedure to streamline practice and to provide guidance for new centres commencing the technique. METHODS: Between October 2021 and October 2023 a series of face to face online and hybrid meetings were held in which a modified Delphi process was used to develop a unified consensus document. After each meeting the document was modified and recirculated and then rediscussed at subsequent meeting until a greater than 90% consensus was achieved in all recommendations. RESULTS: The completed consensus document comprised 23 topics in which greater than 90% consensus was achieved, with 83% of recommendations having 100% consensus across all members of the working group. The consensus recommendations covered all areas of the surgical procedure including pre-operative assessment, drug dosing and administration, perfusion parameters, hyperthermia, leakage monitoring and theatre logistics, practical surgical strategies and also post-operative care, response evaluation and staff training. CONCLUSION: We present the first joint expert-based consensus statement with respect to the technical aspects of ILP that can serve as a reference point for both existing and new centres in providing ILP.


Sujet(s)
Perfusion régionale de chimiothérapie anticancéreuse , Membres , Humains , Perfusion régionale de chimiothérapie anticancéreuse/méthodes , Consensus , Méthode Delphi , Membres/vascularisation , Tumeurs , Facteur de nécrose tumorale alpha
7.
Surg Oncol ; 52: 102017, 2024 Feb.
Article de Anglais | MEDLINE | ID: mdl-38091877

RÉSUMÉ

BACKGROUND: Pleomorphic dermal sarcoma (PDS) of the scalp is a rare tumour which is usually slow growing, but occasionally displays rapid growth and has a low rate of local recurrence. Surgical resection is the mainstay of treatment, with or without radiotherapy. The aim of this study is to describe the surgical approach and the additional benefit of radiotherapy to the treatment of these patients. METHODS: Retrospective, single-centre analysis of patients with PDS of the scalp that underwent surgical resection between 2007 and 2021 (n = 24). Treatment variables including depth of resection (superficial or deep to the galea aponeurotica) and adjuvant radiotherapy were investigated. RESULTS: Twenty-four patients were included in this study. Median age was 80 (range, 52-95), with a median ASA score of 3 (2-3). Sixteen (66.6 %) patients underwent surgical resection including the galea, while the rest (n = 8) did not or was not known. Radiotherapy was given in 7 (29 %) patients in which only 3 (12.5 %) were in the galeal resection group. Reasons for radiotherapy administration were concomitant SCC found at the same area of resection and close margins. In a median follow-up of was 26.2 months (range, 13.6-102.5) there was only one recurrence event. CONCLUSIONS: PDS of the scalp can be safely managed with a surgical resection if clear surgical margins are achieved without radiotherapy with good oncological outcomes.


Sujet(s)
Sarcomes , Tumeurs cutanées , Humains , Sujet âgé de 80 ans ou plus , Sarcomes/chirurgie , Sarcomes/anatomopathologie , Études rétrospectives , Cuir chevelu/chirurgie , Cuir chevelu/anatomopathologie , Tumeurs cutanées/chirurgie , Radiothérapie adjuvante , Récidive tumorale locale/chirurgie
8.
Eur J Surg Oncol ; 50(1): 107301, 2024 Jan.
Article de Anglais | MEDLINE | ID: mdl-38041960

RÉSUMÉ

INTRODUCTION: High rates of local recurrence (LR) have been reported following resection of extremity Atypical lipomatous tumours/Well-differentiated liposarcomas (ALTs). This retrospective study of patients who underwent resection of primary deep extremity and trunk ALTs at a specialist sarcoma centre aims to assess morbidity and factors associated with low local recurrence rates (LRR). METHODS: To review a homogeneous cohort of patients with low-grade disease, tumours with known high-risk histological features were excluded. Prognostic variables potentially influencing local recurrence (LR) (age, size, site, margin status, and histological findings) were analysed. Endpoints were LR, distant recurrence (DR) and local disease-free survival (LDFS). RESULTS: 127 patients were identified, with median follow-up of 54 months (0-235). Median tumour size was 17.5 cm (5-36). 85 % occurred in the lower limb. 93.7 % underwent marginal resection. No patients received radiotherapy. Median hospital stay was 3 days (0-16). 7.9 % returned to theatre for evacuation of haematoma or infected seroma and 18.1 % had outpatient seroma aspiration. Surgical margins were R0/R1 in 93.7 % of patients and R2 in 6.3 % with a LR rate of 8.4 % and 75 % respectively at median time of 54 months. One- and 5-year LDFS was 100 % and 88.4 %, respectively. DR rate was 0.8 % (1/127) this patient had pleomorphic liposarcomatous transformation on recurrence and subsequently developed distant metastases. No patients died of disease. CONCLUSION: Function-preserving marginal resection of non-coelomic ALTs has low morbidity, low LR and extremely low rates of distant relapse. Patients with lower limb ALT were found to have significantly lower LR, which may impact follow-up protocols.


Sujet(s)
Liposarcome , Tumeurs des tissus mous , Humains , Études rétrospectives , Sérome , Récidive tumorale locale/chirurgie , Liposarcome/anatomopathologie , Membre inférieur , Tumeurs des tissus mous/chirurgie , Tumeurs des tissus mous/anatomopathologie
10.
Eur J Cancer ; 190: 112949, 2023 09.
Article de Anglais | MEDLINE | ID: mdl-37453241

RÉSUMÉ

OBJECTIVE: The aim of this study was to investigate the response rates of different extremity soft-tissue sarcoma subtypes (eSTS) after isolated limb perfusion (ILP), based on an international multi-centre study. MATERIALS AND METHODS: The retrospective cohort comprised eSTS patients from 17 specialised ILP centres that underwent melphalan-based ILP, with or without recombinant human tumour necrosis factor (rhTNFα) (TM-ILP and M-ILP, respectively). Response was measured on imaging (magnetic resonance imaging) and/or clinical response, for which M-ILPs were excluded. RESULTS: A total of 1109 eSTS patients were included. The three most common histological subtypes were undifferentiated pleomorphic sarcoma (17%, n = 184), synovial sarcoma (16%, n = 175) and myxofibrosarcoma (8%, n = 87). rhTNFα was used in 93% (TM-ILP) and resulted in a significantly better overall response rate (ORR, p = 0.031) and complete responses (CR, p < 0.001) in comparison to M-ILP, without significant differences among histological subgroups. The ORR of TM-ILP was 68%, including 17% CR. Also, 80% showed progressive disease. Significantly higher response rates were shown for Kaposi sarcoma (KS) with 42% CR and 96% ORR (both p < 0.001), and significantly higher CR rates for angiosarcoma (AS, 45%, p < 0.001) and clear cell sarcoma (CCS, 31%, p = 0.049). ILP was followed by resection ≤ 6 months in 80% of the patients. The overall limb salvage rate was 88%, without significant differences among histological subgroups, but was significantly higher for ILP responders compared to non-responders (93% versus 76%, p < 0.001). CONCLUSION: ILP resulted in high response and LRS among all eSTS subtypes, however, with significant differences between subtypes with most promising results for KS, AS and CCS.


Sujet(s)
Sarcome de Kaposi , Sarcomes , Tumeurs des tissus mous , Adulte , Humains , Études rétrospectives , Perfusion régionale de chimiothérapie anticancéreuse/méthodes , Sarcomes/anatomopathologie , Melphalan/usage thérapeutique , Membres/anatomopathologie , Tumeurs des tissus mous/anatomopathologie , Perfusion , Facteur de nécrose tumorale alpha , Antinéoplasiques alcoylants/usage thérapeutique
12.
Ann Surg ; 278(2): 267-273, 2023 08 01.
Article de Anglais | MEDLINE | ID: mdl-35866666

RÉSUMÉ

OBJECTIVE: The Transatlantic Australasian Retroperitoneal Sarcoma Working Group conducted a retrospective study on the disease course and clinical management of ganglioneuromas. BACKGROUND: Ganglioneuromas are rare tumors derived from neural crest cells. Data on these tumors remain limited to case reports and single-institution case series. METHODS: Patients of all ages with pathologically confirmed primary retroperitoneal, intra-abdominal, and pelvic ganglioneuromas between January 1, 2000, and January 1, 2020, were included. We examined demographic, clinicopathologic, and radiologic characteristics, as well as clinical management. RESULTS: Overall, 328 patients from 29 institutions were included. The median age at diagnosis was 37 years with 59.1% of patients being female. Symptomatic presentation comprised 40.9% of cases, and tumors were often located in the extra-adrenal retroperitoneum (67.1%). At baseline, the median maximum tumor diameter was 7.2 cm. One hundred sixteen (35.4%) patients underwent active surveillance, whereas 212 (64.6%) patients underwent resection with 74.5% of operative cases achieving an R0/R1 resection. Serial tumor evaluations showed that malignant transformation to neuroblastoma was rare (0.9%, N=3). Tumors undergoing surveillance had a median follow-up of 1.9 years, with 92.2% of ganglioneuromas stable in size. With a median follow-up of 3.0 years for resected tumors, 84.4% of patients were disease free after resections, whereas recurrences were observed in 4 (1.9%) patients. CONCLUSIONS: Most ganglioneuromas have indolent disease courses and rarely transform to neuroblastoma. Thus, active surveillance may be appropriate for benign and asymptomatic tumors particularly when the risks of surgery outweigh the benefits. For symptomatic or growing tumors, resection may be curative.


Sujet(s)
Ganglioneurome , Neuroblastome , Tumeurs du rétropéritoine , Sarcomes , Tumeurs des tissus mous , Humains , Femelle , Adulte , Mâle , Études rétrospectives , Ganglioneurome/chirurgie , Tumeurs du rétropéritoine/chirurgie , Sarcomes/chirurgie , Sarcomes/anatomopathologie , Évolution de la maladie
13.
Surg Oncol ; 45: 101871, 2022 Dec.
Article de Anglais | MEDLINE | ID: mdl-36270156

RÉSUMÉ

BACKGROUND: The role of en bloc vascular resection and reconstruction (EVRR) is controversial in colorectal adenocarcinoma (CRC), but well-established in retroperitoneal sarcoma (RPS). Sparse data exists regarding these complex procedures. METHODS: Patients undergoing curative intent EVRR for advanced CRC and RPS between 2014 and 2021 at a tertiary centre were included. Morbidity, margins, recurrence, and survival were evaluated. RESULTS: 24 patients underwent EVRR with 48 reconstructions (11 CRC and 13 RPS). For CRC, 100% of patients underwent Iliac system reconstructions. For RPS, inferior vena cava reconstructions were the most common (69.2%). There were 2 arterial and 1 venous graft thromboses. Primary graft patency was 89.4% arterial and 93.1% venous, while secondary patency was 100% arterial and 96.5% venous at last follow up. 1 venous and 1 arterial graft required reoperation for bleeding. There were no compromised limbs. Major complications occurred in 6 patients (25.0%) with no observed difference between CRC and RPS (OR 0.43 95%CI[0.60,3.19], P = 0.41). R1 margins occurred 1 CRC (90.9%) and 3 RPS (76.9%), with no R2 resections. All vascular resection margins were clear. There were 6 CRC (50%) and 4 RPS (33.3%) recurrences. Median recurrence time was 20.9 months for CRC and 'not yet reached' for RPS. Median follow-up was 19.4 months for CRC and 21.4 months for RPS. CONCLUSION: EVRR for locally advanced CRC or RPS is safe and achieves favorable R0 resection rates. CRC patients with major vascular invasion can still be considered for curative intent surgery. Larger cohorts with longer follow up are needed to assess oncologic outcomes.


Sujet(s)
Adénocarcinome , Tumeurs colorectales , Tumeurs du rétropéritoine , Sarcomes , Tumeurs des tissus mous , Humains , Études rétrospectives , Marges d'exérèse , Centres de soins tertiaires , Résultat thérapeutique , Tumeurs du rétropéritoine/anatomopathologie , Sarcomes/anatomopathologie , Tumeurs colorectales/chirurgie , Tumeurs colorectales/anatomopathologie , Adénocarcinome/chirurgie , Récidive tumorale locale/chirurgie
14.
Ann Surg Oncol ; 29(12): 7335-7348, 2022 Nov.
Article de Anglais | MEDLINE | ID: mdl-35767103

RÉSUMÉ

BACKGROUND: Surgery is the mainstay of treatment for retroperitoneal sarcoma (RPS), but local recurrence is common. Biologic behavior and recurrence patterns differ significantly among histologic types of RPS, with implications for management. The Transatlantic Australasian RPS Working Group (TARPSWG) published a consensus approach to primary RPS, and to complement this, one for recurrent RPS in 2016. Since then, additional studies have been published, and collaborative discussion is ongoing to address the clinical challenges of local recurrence in RPS. METHODS: An extensive literature search was performed, and the previous consensus statements for recurrent RPS were updated after review by TARPSWG members. The search included the most common RPS histologic types: liposarcoma, leiomyosarcoma, solitary fibrous tumor, undifferentiated pleomorphic sarcoma, and malignant peripheral nerve sheath tumor. RESULTS: Recurrent RPS management was evaluated from diagnosis to follow-up evaluation. For appropriately selected patients, resection is safe. Nomograms currently are available to help predict outcome after resection. These and other new findings have been combined with expert recommendations to provide 36 statements, each of which is attributed a level of evidence and grade of recommendation. In this updated document, more emphasis is placed on histologic type and clarification of the intent for surgical treatment, either curative or palliative. Overall, the fundamental tenet of optimal care for patients with recurrent RPS remains individualized treatment after multidisciplinary discussion by an experienced team with expertise in RPS. CONCLUSIONS: Updated consensus recommendations are provided to help guide decision-making for treatment of locally recurrent RPS and better selection of patients who would potentially benefit from surgery.


Sujet(s)
Produits biologiques , Liposarcome , Tumeurs du rétropéritoine , Sarcomes , Tumeurs des tissus mous , Adulte , Humains , Récidive tumorale locale/chirurgie , Tumeurs du rétropéritoine/anatomopathologie , Tumeurs du rétropéritoine/chirurgie , Études rétrospectives , Sarcomes/anatomopathologie , Sarcomes/chirurgie
15.
Ann Surg Oncol ; 28(12): 7873-7888, 2021 Nov.
Article de Anglais | MEDLINE | ID: mdl-33852100

RÉSUMÉ

BACKGROUND: Retroperitoneal soft tissue sarcomas comprise a heterogeneous group of rare tumors of mesenchymal origin that include several well-defined histologic subtypes. In 2015, the Transatlantic Australasian RPS Working Group (TARPSWG) published consensus recommendations for the best management of primary retroperitoneal sarcoma (RPS). Since then, through international collaboration, new evidence and knowledge have been generated, creating the need for an updated consensus document. METHODS: The primary aim of this study was to critically evaluate the current evidence and develop an up-to-date consensus document on the approach to these difficult tumors. The resulting document applies to primary RPS that is non-visceral in origin, with exclusion criteria as previously described. The relevant literature was evaluated and an international group of experts consulted to formulate consensus statements regarding the best management of primary RPS. A level of evidence and grade of recommendation were attributed to each new/updated recommendation. RESULTS: Management of primary RPS was considered from diagnosis to follow-up. This rare and complex malignancy is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, and an individualized management plan should be made based on the 29 consensus statements included in this article, which were agreed upon by all of the authors. Whenever possible, patients should be enrolled in prospective trials and studies. CONCLUSIONS: Ongoing international collaboration is critical to expand upon current knowledge and further improve outcomes of patients with RPS. In addition, prospective data collection and participation in multi-institution trials are strongly encouraged.


Sujet(s)
Tumeurs osseuses , Tumeurs du rétropéritoine , Sarcomes , Tumeurs des tissus mous , Adulte , Consensus , Humains , Tumeurs du rétropéritoine/chirurgie , Sarcomes/thérapie
16.
J Surg Oncol ; 123(1): 117-126, 2021 Jan.
Article de Anglais | MEDLINE | ID: mdl-33084061

RÉSUMÉ

BACKGROUND AND OBJECTIVES: Limited literature exists examining the immune microenvironment in liposarcoma, particularly with regard to the impact of radiotherapy. A major problem is the lack of scoring system for the tumour-infiltrating lymphocytes (TILs) in sarcoma. This study aims to describe the immune environment pre- and postradiotherapy and identify the optimal immune infiltrate scoring system for sarcoma. METHODS: Thirty-nine paired tissue samples (pre- and postradiotherapy) from patients with liposarcoma were scored by two pathologists for TILs using pre-existing systems (for breast cancer and melanoma) and compared for interobserver reliability. Immunohistochemical staining was performed for various immune markers. RESULTS: The TIL scoring system for breast cancer yielded perfect agreement (κ = 1.000). 21% of patients had increased TILs after radiotherapy, 87.5% of whom had dedifferentiated liposarcoma. Immune suppressor expression was increased frequently after radiotherapy (CD68 increased in 59.4%, PD-L1 increased in 25%). Immune effector expression (CD8) was unchanged in 84.4%. CONCLUSIONS: Breast cancer TIL scoring is reproducible in liposarcoma and has high interobserver reliability. Radiotherapy was observed to have a limited impact on immune effectors but seemed to have more impact in upregulating immune suppressors, suggesting radiotherapy may contribute to disease control through immunomodulatory effects. Dedifferentiated liposarcoma represents a uniquely responsive subtype.


Sujet(s)
Lymphocytes T CD8+/immunologie , Liposarcome/immunologie , Lymphocytes TIL/immunologie , Récidive tumorale locale/immunologie , Radiothérapie/méthodes , Microenvironnement tumoral/immunologie , Adolescent , Adulte , Sujet âgé , Lymphocytes T CD8+/effets des radiations , Femelle , Études de suivi , Humains , Liposarcome/anatomopathologie , Liposarcome/radiothérapie , Lymphocytes TIL/effets des radiations , Mâle , Adulte d'âge moyen , Récidive tumorale locale/anatomopathologie , Récidive tumorale locale/radiothérapie , Pronostic , Études rétrospectives , Microenvironnement tumoral/effets des radiations , Jeune adulte
17.
J Cutan Pathol ; 47(12): 1115-1122, 2020 Dec.
Article de Anglais | MEDLINE | ID: mdl-32529651

RÉSUMÉ

BACKGROUND: Prostate-specific membrane antigen (PSMA) is a prostatic epithelial protein that is used as a radiotracer (68Ga-PSMA-11) for prostate cancer staging. PSMA-PET/CT (positron emission tomography/computed tomography) performed for prostate cancer has been observed to detect melanoma metastases. The aim of this study was to investigate the performance of PSMA immunohistochemistry on resected melanoma metastases to explore its use as a diagnostic imaging biomarker for melanoma. METHODS: A total of 41 specimens with stage III/IV melanoma were stained with PSMA immunohistochemistry. All specimens required both disease and control regions. Two pathologists scored the specimens and a receiver operating characteristic (ROC) curve was plotted. Western blot and multiplex immunofluorescence were also performed. RESULTS: The area under the ROC curve was 0.82, suggesting that PSMA has excellent discriminatory power in melanoma metastases. Sensitivity is 82.9% and specificity 73.2%. Immunohistochemistry and Western blot reveal that PSMA staining in melanoma consistently and most intensely occurs in tumor neovasculature. Multiplex immunofluorescence shows that melanocytes may also weakly express PSMA. CONCLUSION: The performance of PSMA immunohistochemistry in melanoma metastases contrasts with that reported in prostate cancer studies. This study indicates that PSMA shows promise for use as a novel biomarker in melanoma and justifies further research in the clinical setting with potential as a PET/CT radiotracer and intraoperative fluorescence marker for melanoma.


Sujet(s)
Antigènes de surface/métabolisme , Glutamate carboxypeptidase II/métabolisme , Métastase lymphatique/anatomopathologie , Mélanome/métabolisme , Mélanome/secondaire , Tumeurs de la prostate/métabolisme , Tumeurs cutanées/métabolisme , Tumeurs cutanées/secondaire , Marqueurs biologiques tumoraux/métabolisme , Humains , Immunohistochimie/méthodes , Mâle , Mélanocytes/métabolisme , Mélanome/imagerie diagnostique , Mélanome/chirurgie , Stadification tumorale/méthodes , Anatomopathologistes , Tomographie par émission de positons couplée à la tomodensitométrie/méthodes , Tumeurs de la prostate/diagnostic , Tumeurs de la prostate/anatomopathologie , Courbe ROC , Études rétrospectives , Sensibilité et spécificité , Tumeurs cutanées/imagerie diagnostique , Tumeurs cutanées/chirurgie ,
18.
ANZ J Surg ; 90(4): 497-502, 2020 04.
Article de Anglais | MEDLINE | ID: mdl-32064728

RÉSUMÉ

BACKGROUND: Retroperitoneal sarcomas are rare soft tissue tumours accounting for 10-15% of soft tissue sarcomas. Patient prognosis and treatment recommendations (including extent of surgery and neoadjuvant strategies) are determined by the pre-operative histopathological subtype and grade obtained from biopsy and thus it is important to understand the accuracy of biopsy in retroperitoneal masses. METHODS: This study presents a case series of primary retroperitoneal sarcomas managed at Peter MacCallum Cancer Centre (PMCC) between 2008 and 2019. Statistical analyses were performed to determine correlation between histopathology from percutaneous biopsy and surgical excision. RESULTS: A total of 117 patients who underwent percutaneous core biopsy and surgical excision of retroperitoneal sarcoma were included. Diagnostic accuracy varied with histopathological diagnosis, but overall precise concordance between biopsy and final histopathology was seen in 61% (κ = 0.57). Biopsy was most sensitive for identifying well-differentiated liposarcoma (WDLPS) (sensitivity 85%, 95% CI 0.06-0.96) and leiomyosarcoma (sensitivity 81%, 95% CI 0.54-0.96) and was least sensitive for identifying de-differentiated liposarcoma (DDLPS) (sensitivity 40%, 95% CI 0.25-0.56). Overall agreement between biopsy and final histopathology increased with use of PET/CT scan pre-biopsy and with use of fluorescence in situ hybridisation testing on biopsy, however, neither test improved recognition of de-differentiated components within WD/DDLPS on core biopsy. CONCLUSIONS: Pre-operative biopsy is important for clinical decision making in the treatment of retroperitoneal sarcoma. A significant portion of patients with a WDLPS will have a de-differentiated component identified at the time of resection that was not identified on initial biopsy.


Sujet(s)
Tumeurs du rétropéritoine , Sarcomes , Tumeurs des tissus mous , Biopsie , Humains , Tomographie par émission de positons couplée à la tomodensitométrie , Tumeurs du rétropéritoine/imagerie diagnostique , Tumeurs du rétropéritoine/chirurgie , Études rétrospectives , Sarcomes/imagerie diagnostique , Sarcomes/chirurgie
19.
Eur J Surg Oncol ; 46(5): 893-897, 2020 05.
Article de Anglais | MEDLINE | ID: mdl-32067874

RÉSUMÉ

INTRODUCTION: Iliocaval leiomyosarcoma (ICLM) is a rare and aggressive form of sarcoma within the retroperitoneum. Surgery is the mainstay of treatment, with no consensus on the benefit of chemoradiotherapy in the neo/adjuvant setting. This study aims to describe the natural history of a chemotherapy-naïve ICLM treated in a tertiary cancer centre and to explore potential directions to improve oncological outcome. MATERIALS AND METHODS: A prospective database was used to identify patient demographics, clinicopathological variables and oncological outcomes in 30 patients who underwent surgical resection in our institution for primary non-metastatic ICLM between 2003 and 2018. RESULTS: There was no 90-day mortality. With a median follow-up time of 70.0 months (95% CI 52.6-87.4), 5/30 patients (16.7%) developed local recurrence while 11/30 (36.7%) developed distant metastatic disease. 1 patient (3.3%) developed both local and distant recurrence. Median overall survival of our cohort was 41.0 months (95% CI 33.6-48.4) and 5-year overall survival rate was 32.1%. Multivariate survival analysis using the Cox proportional hazard model identified tumour grade and blood loss of more than 600 mL as key prognostic factors in our model. CONCLUSION: Management of ICLM should be centralised in high-volume sarcoma centres with expertise in the management of retroperitoneal sarcomas. Integration of tumour biology with a concerted effort to conduct conclusive multi-centre phase III in histological and molecularly defined sarcoma subgroups is necessary to improve patient outcome. We eagerly await the results of STRASS 2 study to gain more insights to the efficacy of neoadjuvant chemotherapy on patient prognosis.


Sujet(s)
Veine iliaque commune/chirurgie , Léiomyosarcome/chirurgie , Tumeurs du rétropéritoine/chirurgie , Tumeurs vasculaires/chirurgie , Veine cave inférieure/chirurgie , Sujet âgé , Perte sanguine peropératoire , Femelle , Humains , Veine iliaque commune/anatomopathologie , Léiomyosarcome/anatomopathologie , Mâle , Marges d'exérèse , Adulte d'âge moyen , Analyse multifactorielle , Grading des tumeurs , Récidive tumorale locale , Durée opératoire , Modèles des risques proportionnels , , Tumeurs du rétropéritoine/anatomopathologie , Taux de survie , Tumeurs vasculaires/anatomopathologie , Procédures de chirurgie vasculaire , Veine cave inférieure/anatomopathologie
20.
Ann Surg Oncol ; 27(3): 919-923, 2020 Mar.
Article de Anglais | MEDLINE | ID: mdl-31664620

RÉSUMÉ

BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is a dermal sarcoma often diagnosed by excision biopsy, and is often incompletely excised, with high recurrence rates. Traditional wide excision involves resection margins of 2-4 cm, often resulting in morbid procedures requiring surgical reconstruction. An alternative is conservative re-excision (CRE), which results in narrower margins and less-frequent reconstruction. The aim of this study is to assess the effectiveness of CRE in providing local control. PATIENTS AND METHODS: A retrospective review of patients treated for DFSP at a tertiary sarcoma centre over a 10-year period. RESULTS: Ninety-eight patients were analysed. Median follow-up was 53 months. Fifty-four patients had microscopically incompletely excised DFSP, and of these, 41 underwent CRE of DFSP scar. Seven (17.1%) patients required more than one CRE to achieve negative margins. The mean width of CRE was 15.4 mm. Fifty-four patients had resection of intact tumours, with 19 (35.2%) requiring surgical reconstruction. One patient (1%) developed local recurrence, and one patient (1%) distant recurrence-both of these patients had high-grade fibrosarcomatous DFSP. No patient with classical DFSP who had clear margins sustained recurrence, regardless of whether their surgery was CRE of scar or wide excision of tumour. CONCLUSIONS: CRE is a safe and acceptable alternative to traditional wide excision, with no patients developing local recurrence (LR). CRE results in low rates of surgical reconstruction, and hence lower morbidity; this is partially offset by the higher rates of inadequate excision requiring further surgery. However, the lesser rate of inadequate excision compared with rates of reconstruction makes CRE an attractive option.


Sujet(s)
Dermatofibrosarcome/chirurgie , Procédures chirurgicales dermatologiques/méthodes , Marges d'exérèse , Récidive tumorale locale/chirurgie , Réintervention/méthodes , Tumeurs cutanées/chirurgie , Dermatofibrosarcome/anatomopathologie , Études de suivi , Humains , Récidive tumorale locale/anatomopathologie , Pronostic , Études rétrospectives , Tumeurs cutanées/anatomopathologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE